In the case of thrombotic and obstetrically complicating anti-phospholipid syndrome (APS), persistent (measured at least 12 weeks apart) lupus anticoagulant (LAC), anti-cardiolipin (aCL), and aβ2-GP I autoantibodies are part of the 2023 ACR/EULAR anti-phospholipid syndrome classification criteria [159]. Here, GPI is linked to autoimmune polyendocrinopathy.